Veli‐Matti Leppänen

Åbo Akademi University — Finland

Biochemistry, Genetics and Molecular Biology · Life Sciences

33h-index4.8kcitations95works36.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Angiogenesis and VEGF in Cancer(28), Lymphatic System and Diseases(22), Renal cell carcinoma treatment(20), Cell Adhesion Molecules Research(11), Nerve injury and regeneration(6)

Publications95 total

EPLINα controls integrin recycling from Rab21 endosomes to drive breast cancer cell migration
Developmental Cell·2025· 4 citedOpen Access
The role and regulation of integrins in cell migration and invasion
Nature Reviews Molecular Cell Biology·2024· 126 cited
EPLINα controls integrin recycling from Rab21 endosomes to drive breast cancer cell migration
2024· 2 citedOpen Access
Loss-of-function mutations of the TIE1 receptor tyrosine kinase cause late-onset primary lymphedema
Journal of Clinical Investigation·2024· 12 citedOpen Access
Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models
Vaccine·2023· 12 citedOpen Access
Table S2 from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Figure S5 from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Table S1 from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Figure S1 from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Figure S4 from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Figure S3 from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Table S2 from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Figure S1 from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Table S1 from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Data from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Figure S3 from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Supplementary Methods and Materials from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Data from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Figure S2 from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
Figure S5 from Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Kari Alitalo(32), Michael Jeltsch(15), Andrey Anisimov(13), Adrian Goldman(10), Pipsa Saharinen(9), Märt Saarma(7), Nisse Kalkkinen(6), Sawan Kumar Jha(6), Denis Tvorogov(6), Tuomas Tammela(5), Kurt Ballmer‐Hofer(5), Lauri Eklund(4), Georgia Zarkada(4), Tanja Holopainen(4), Seppo Ylä‐Herttuala(4), Pia Runeberg‐Roos(4), Harri Nurmi(3), Riikka Kivelä(3), Kaisa Kisko(3), Seppo Kaijalainen(3)